Michael Atkins, MD, Georgetown University, Washington, DC discusses the Phase II study of front line therapy with nivolumab and salvage nivolumab and ipilimumab in patients with advanced renal cell carcinoma (NCT03117309). This video was recorded via an online conference call with the Video Journal of Oncology (VJOncology).
